Short answer
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K current report with the SEC on May 21, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Interim CFO appointment for Mr. Silver, with monthly assignment fee of $12,250.
IRONWOOD PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Interim CFO appointment for Mr. Silver, with monthly assignment fee of $12,250
- Fee continues until permanent CFO appointment or interim assignment termination
- 25,000 RSUs granted under 2019 equity plan, creating potential shareholder dilution
- RSUs vest 50% on each approximate anniversary over two years
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IRONWOOD PHARMACEUTICALS INC 8-K filings
Get the next IRWD 8-K as it lands
Follow IRWD for push alerts, or ask the research agent what this filing means.